Regeneron scored another first on Wednesday. Nearly seven months after getting the FDA’s nod for its first gene therapy, Regeneron secured approval its first siRNA therapy, which also happens to be a first-in-class option for generalized myasthenia gravis.
Late Wednesday evening, the FDA greenlit cemdisiran—to be marketed as Livsayis—for adults with gMG who are positive for anti-acetylcholine receptors. This is the most common type of the autoimmune disease, according to Regeneron’s release.